Background
Hemostatic disturbances with coronavirus disease 2019 (COVID‐19) can predispose to tricuspid and right heart thrombi in very rare instances.
Aim
We describe a 29‐year‐old female patient without a previous cause of thrombosis who developed large tricuspid valve thrombus (TVT) and moderate‐to‐severe tricuspid regurgitation (TR) during the course of COVID‐19 infection.
Materials and Methods
Persistant fever and tachycardia with thrombocytopenia and high
d
‐dimer increased the index of suspicion. The diagnosis was made by bedside transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR). Surgery was performed for thrombectomy and tricuspid valve replacement with a tissue valve.
Discussion and conclusion
Detection of TVT in COVID‐19 patients on the basis of high index of suspicion, bedside TTE and noninvasive CMR helps early surgical treatment and subsequent reduction of mortality and hospital stay.
Background and objectives:The aim of the present study is to evaluate and compare IgG-binding to megakaryocytes in bone marrow of ITP and MDS patients to determine megakaryocytes targeting by autoantibodies in vivo as a mechanism of platelet underproduction in these disorders. Subjects and methods: The study was carried out on 20 ITP (group I) patients and 20 thrombocytopenic patients with myelodysplastic syndrome (group II) who were admitted to minia university hospital. Serial histological sections from bone marrow biopsies were stained for IgG. Results: high IgG binding was found in ITP and MDS patients (group I & II ) and there was no statistically significant difference between both groups ((14/20 (70%) vs. 13/20 (65%),), (P value =0.736). Conclusion: Antibody binding to megakaryocytes in a proportion of MDS patients suggests that immune mediated mechanism underlies PLT underproduction in those patients
Background: Hemostatic disturbances with coronavirus disease
2019 (COVID-19) can predispose to tricuspid and right heart thrombi in
very rare instances. Aim: We describe a 29-year-old female
patient without previous cause of thrombosis who developed large
tricuspid valve thrombus (TVT) and moderate-to-severe tricuspid
regurgitation (TR) during the course of COVID-19 infection.
Materials and methods: Persistant fever and tachycardia with
thrombocytopenia and high D-dimer increased the index of suspicion. The
diagnosis was made by bedside transthoracic echocardiography (TTE) and
cardiac magnetic resonance (CMR). Surgery was performed for thrombectomy
and tricuspid valve replacement with a tissue valve. Discussion
and conclusion: Detection of TVT in COVID-19 patients on the basis of
high index of suspicion, bedside TTE and non-invasive CMR helps early
surgical treatment and subsequent reduction of mortality and hospital
stay.
Introduction:Sepsis is a life threatening condition which affects many children, Sepsis is said to be one of the leading causes of death among children even in advanced countries. Aim of the work: to verify the association between cardiac dysfunction and serum ferritin level with unfavorable outcomes in pediatric sepsis. Patients and Methods: This prospective cohort study was carried out on 40 patients with suspected or confirmed sepsis in our PICU. All patients in the study were subjected for assay of serum levels of ferritin, CRP and echocardiography on Day of admission & Day 3. Results: Serum Ferritin level was significantly higher among cases with cardiac dysfunction than cases without cardiac dysfunction. There was highly statistically significant difference between day of admission D1 and third day as regard to serum ferritin level and CRP with median value of Ferritin level and CRP were higher on the day of admission compared to third day.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.